Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
1999-09-23
2003-04-08
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S002600, C514S564000
Reexamination Certificate
active
06545048
ABSTRACT:
One-third of all individuals in the United States alone will develop cancer. Although the five year survival rate has risen dramatically nearly fifty percent as a result of progress in early diagnosis and therapy, cancer still remains second only to cardiac disease as a cause of death in the United States. Twenty percent of Americans die from cancer, half due to lung, breast, and colon-rectal cancer. Moreover, skin cancer remains a health hazard.
Designing effective treatments for patients with cancer has represented a major challenge. The current regimen of surgical resection, external beam radiation therapy, and/or systemic chemotherapy has been partially successful in some kinds of malignancies, but has not produced satisfactory results in others. One approach to treating cancer has been to induce apoptosis (cell death) of targeted tumor cells; therefore, mechanisms inducing apoptosis are of interest. One such mechanism has been reported where the Fas ligand, (FasL) (also known as CD95L and APO-IL), a cell surface molecule belonging to the tumor necrosis factor family, induces apoptosis of Fas-bearing tumor cells. Seino, et al.,
Nature Med.,
3(2):165 (1997).
In another approach, cancer cell lines have been characterized. For example, it has been reported that all human melanoma lines tested in a number of studies express endothelin B-receptor (ETRB) (Yohn, et al.,
Biochem. Biophys. Res. Commun
., 201:449-57 (1994); Kikuchi, et al.,
Biochem. Biophys. Res. Commun.,
219:734-9 (1996); Ohtani, et al.,
Biochem. Biophys. Res. Commun.,
234:526-30 (1997); Zhang, et al.,
Brit. J. Cancer,
78:1141-6 (1988)); moreover, expression is correlated with their differentiation state. Increased endothelin A-receptor (ETRA) expression is associated with induced differentiation of A375 melanoma cells, while they predominantly express ETRB in their malignant state (Ohtani, et al.,
Biochem. Biophys. Res. Commun.,
234:526-30 (1997)). Unfortunately, the roles of endothelin receptors (ETRs) is not clear from previous studies. While one report indicates that endothelin-1 (ET1), acting through the ETRB, mediates mitogenic and chemokinetic effects on melanoma cells (Yohn, et al.,
Biochem. Biophys. Res. Commun.,
201:449-57 (1994)), another report suggests other mechanisms for ET1 (Okazawa, et al.,
J. Biol. Chem.,
273:12584-92 (1998)). Moreover, at least in one study, the focus of ETRB has been in regards to hypertension (Hashimoto, et al.,
Biol. Pharm. Bull.,
21(8):800-804 (1998)). Additionally, endothelin-3 (ET3) has been reported on, however, many such reports are regarding developing non-malignant (normal) cells (Lahau, et al.,
PNAS,
93:3892-7 (1996)).
Studies have reported on ETRA and ET1 activity in regards to malignant cells, however, these studies were performed in vitro. For example, see, Nelson, et al., Cancer Res., 56:663-8 (1996).
Therefore, there remains a need to identify compounds which can be used in vivo to treat diseases such as cancer. In particular, there is a need to be able to selectively target malignant cells and induce cell death.
SUMMARY OF THE INVENTION
The present invention provides compositions and methods of treatment. In one aspect, a method of treating cancer is provided. In one embodiment, the method comprises administering to an individual in need of treatment for cancer, an inhibitor of an endothelin receptor activity, in a therapeutically effective amount. Preferably, the receptor is an endothelin B- or A-receptor. Administration can occur by a number of methods known in the art including by administration directly to the tumor site, or preferably, administration is systemic.
In one aspect, any kind of cancer is treated. Preferably, the cancer is skin, ovarian or prostrate cancer. In another preferred embodiment, the cancer is in a metastatic state.
In one embodiment, the inhibitor is an endothelin B-receptor or A-receptor antagonist. In a preferred embodiment, the inhibitor is BQ788 or a derivative thereof. In another preferred embodiment, the inhibitor is an antisense molecule to an endothelin receptor nucleic acid or an endothelin receptor agonist nucleic acid.
In another aspect, the invention provides a method for reducing abnormal proliferation or inducing differentiation of a cell. In a preferred embodiment, said cell comprises an endothelin receptor, preferably, an endothelin B-receptor. In one embodiment, the method comprising administering an inhibitor to an endothelin receptor to said cell in an amount for reducing proliferation or inducing differentiation. In yet another embodiment, a method for inducing apoptosis in a cell is provided. One method comprises administering an inhibitor to an endothelinreceptor, preferably an endothelin B-receptor, to said cell in an amount for inducing apoptosis. Preferably, the cell is a cancer cell.
Also provided herein is a method for screening for a bioactive agent capable of interfering with the binding of an endothelin receptor, preferably an endothelin B-receptor, and a ligand. In a preferred embodiment, the method comprises combining an endothelin receptor, a candidate bioactive agent and a ligand, and determining the binding of said receptor and said ligand. Preferably, the ligand is selected from the group consisting of endothelin 3, S6c, BQ-3020, and BQ-788,
In another aspect, a method for delivering a substance to a cancerous cell in an individual is provided. The method comprises conjugating a substance to BQ788 or a derivative thereof to form a conjugate and administering said conjugate to said individual.
REFERENCES:
patent: 5550110 (1996-08-01), Cody et al.
patent: WO 98/41206 (1998-09-01), None
patent: 98/41206 (1998-09-01), None
patent: 00/36918 (2000-06-01), None
Janus et al., “ABT-627, endothelin-receptor antagonist, for advanced caner: Phase I pharmacokinetic results,” Abstract to Proc. Amer. Canc. Res. Annual Meeting (04-1999), 40:90-91 Meeeting Info: 90thAnnual Meeting American Association for Cancer.*
Nelson et al., Cancer Res., 56:663-668, Feb. 1996.
Ishikawa et al., Proc. Natl. Acad. Sci. USA, 91:4892-4896, May 1994.
Ohtani et al., Biochem. Biophys. Res. Commun., 234:526-430, 1997, Feb. 1996.
Seino et al., “Antitumor effect of locally produced CD95 ligand”,Nature Med.,3(2):165-170 (Feb. 1997).
Yohn et al., “Human Melanoma Cells Express Functional Endothelin-1 Receptors,”Biochem. Biophys. Res. Commun.,201(1):449-457 (May 1994).
Kikuchi et al., “Decreased ETBReceptor Expression in Human Metastatic Melanoma Cells,”Biochem. Biophys. Res. Commun.,219:734-739 (1996).
Ohtani et al., “Bromodeoxyuridine-Induced Expression of EndothelinAin A375 Human Melanoma Cells,”Biochem. Biophys. Res. Commun.,234:526-530 (1997).
Zhang et al., “Truncated human endothelin receptor A produced by alternative splicing and its expression in melanoma,”Brit. J. Cancer,78(9):1141-1146 (1988).
Okazawa et al., “Endothelin-induced Apoptosis of A375 Human Melanoma Cells,”J. Biol. Chem.,273(20):12584-12592 (1998).
Hashimoto et al., “Endothelin ETBReceptor-Mediated Action on Systemic and Renal Hemodynamics and Urine Formation in Deoxycorticosterone Acetate-Salt-Induced Hypertensive Rats,”Biol. Pharm. Bull.,21(8)800-804 (1998).
Lahav et al., “Endothelin 3 promotes neural crest cell proliferation and mediates a vast incerase in melanocyte number in culture, ”PNAS,93:3892-3897 (Apr. 1996).
Nelson et al., “Endothelin-1 Production and Decreased Endothelin B Receptor Expression in Advanced Prostate Cander,”Cancer Res.,56:663-668 (Feb. 1996).
Bagnato et al., “Expression of Endothelin 1 and Endothelin A Receptor in Ovarian Carcinoma: Evidence for an Autocrine Role in Tumor Growth,”Cancer Res.,59:720-727 (Feb. 1999).
Baynash et al., “Interaction of Endothelin-3 with Endothelin-B Receptor is Essential for Development of Epidermal Melanocytes and Enteric Neurons,”Cell,79:1277-1285 (Dec. 1994).
Ishikawa et al., “Biochemical and pharmacological profile of a potent and selectie endothelin B-receptor antagonists, BQ-799,”Proc. Natl. Acad. Sci. USA,91:4892-4896 (May 1994).
Hashimoto et al., “Endothelin ETBReceptor-Mediated Action on S
Lahav Ronit
Patterson Paul H.
California Institute of Technology
Capps Nancy B.
Jones Dwayne C.
Trecartin Richard F.
LandOfFree
Compositions and methods of treating cancer using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods of treating cancer using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods of treating cancer using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3077510